Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | ESMO 2023 highlights: KEYNOTE-A18 and more

Domenica Lorusso • 23 Oct 2023
ESMO 2023
Cervical Cancer Endometrial Cancer Gynecological Cancer Antibodies Pembrolizumab
KEYNOTE-A18

Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, shares her highlights of the European Society for Medical Oncology (ESMO) 2023 Congress, noting the important clinical implications of the Phase III KEYNOTE-A18 (NCT04221945) trial, as well as noting data supporting the combination of PARP inhibitors and immune therapy in the treatment of patients with endometrial cancer with mismatch repair deficiency (dMMR). This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Domenica Lorusso

0:47
Assessing chemotherapy and immunotherapy in dMMR endometrial cancer
Domenica Lorusso • 23 Oct 2023
0:52
The importance of HRD testing in ovarian cancer
Domenica Lorusso • 23 Oct 2023
1:14
KEYNOTE-A18: pembrolizumab with chemoradiotherapy for advanced cervical cancer
Domenica Lorusso • 23 Oct 2023
5:23
Latest developments in immunotherapy for advanced/recurrent endometrial cancer
Domenica Lorusso • 5 Dec 2022

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals